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Abstract
Organophosphorus (OP) compounds include a broad group of toxic chemicals such as insecticides,
chemical warfare agents and antiwear agents. The liver cytochromes P450 bioactivate many OPs
to potent inhibitors of serine hydrolases. Cholinesterases were the first OP targets discovered and
are the most studied. They are used to monitor human exposures to OP compounds. However, the
assay that is currently used has limitations. The mechanism of action of OP compounds is the
inhibition of serine hydrolases by covalently modifying their active-site serine. After structural
rearrangement, the complex OP inhibitor-enzyme is irreversible and will remain in circulation
until the modified enzyme is degraded. Mass spectrometry is a sensitive technology for analyzing
protein modifications, such as OP-adducted enzymes. These analyses also provide some
information about the nature of the OP adduct. Our aim is to develop high-throughput protocols
for monitoring OP exposures using mass spectrometry.
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1. Introduction
Organophosphorus (OP) compounds were first described at the beginning of the 19th
century by Jean Pierre Boudet, when he generated traces of ‘phosphoric ether’ as a result of
combining alcohol and phosphoric acid [1]. However, it was not until 1848 that Franz Anton
Voegeli created the first OP compound, triethyl phosphate. Just 5 years later, Philippe de
Clermont described the synthesis of the first OP compound with anticholinesterase
properties, the tetraethyl pyrophosphate (TEPP) [1]. In the 1930s, OPs were reported to be
toxicants for mammals and insects, a property that triggered military interest and influenced
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the evolution of OPs into the highly toxic nerve agents sarin, soman and tabun, synthesized
by Gerhard Schrader, considered the ‘father of modern OP compounds’ [2]. After World
War II, OP compounds saw use as a major class of insecticides (e.g., chlorpyrifos, malathion
and parathion), as originally intended by Schrader. In addition to their utility as agriculture
chemicals and warfare agents, OP compounds have also been used in industry as
plasticizers, flame retardants, fuel additives, and lubricants, or even in medicine as
therapeutic agents [3].
OPs are one of the most common causes of poisoning worldwide, with 3 million cases of
pesticide poisonings per year, resulting in 220,000 deaths [4]. Their broad use results in
many cases in environmental or occupational human exposure, causing a variety of adverse
health effects [5]. As a consequence, research on bio-markers for biomonitoring human
exposures to OPs has become an area of extensive investigation.
2. Mechanism of action of OP compounds
OPs comprise a large and diverse family of compounds, many of which can be hydrolyzed
in the presence of water or by specific enzymes, resulting in detoxification. OP insecticides
are mainly derivatives of phosphoric or thiophosphoric acid, containing usually two alkoxy
substituent groups and a third substituent known as the ‘leaving group’, as it is displaced
when the OP interacts with serine hydrolases [6].
The mechanism of action of OP compounds involves the progressive inhibition of serine
hydrolases [7], the main target being acetylcholinesterase (AChE). Their inhibitory action on
AChE at nerve synapses seems to be responsible for their toxicity toward both invertebrates
and mammals [8]. AChE (EC 3.1.1.7, accession #P22303) is a tetrameric serine esterase
present in many tissues, particularly in central and peripheral nervous tissue where it
terminates nerve impulse transmission by hydrolyzing the neuro-transmitter acetylcholine at
nerve synapses. AChE is also found on red blood cells (RBCs), where its function is unclear.
In vertebrates, butyrylcholinesterase (BChE) can also hydrolyze acetylcholine. BChE (EC
3.1.1.8, accession #P06276) is also a tetrameric serine esterase present almost ubiquitously
and in plasma. BChE is also inhibited by OP compounds, although this inhibition has no
cholinergic symptoms and no known biological effect [8, 9]. The physiological function of
BChE is still not clear, although some studies suggest that it could act as an AChE backup
[10–12]. This certainly appears to be the case in the AChE knockout mouse generated by
Lockridge and colleagues [10]. Furthermore, BChE, as a stoichiometric scavenger, may
protect from synthetic and naturally occurring poisons by preventing AChE inhibition by
these toxins [13].
3. Biomonitoring OP exposures
Biomonitoring refers to the assessment of human exposure to chemicals and health risk by
measuring the chemicals or their metabolites in body fluids, such as blood or urine [14].
Early detection of exposures can enable interventions before severe symptoms occur and
follow-up of the recovery of the intoxicated subject.
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The term biomarker refers to biological substances that are indicators of exposure or disease
[15], and that can be measured by laboratory techniques [16]. There is an increasing interest
in identifying and characterizing new biomarkers for a better health assessment.
Blood cholinesterases have long served as biomarkers of OP exposure, since they were the
first OP targets discovered. It has been shown that inhibition of RBC AChE can be used as a
valuable surrogate for inhibition of neuronal AChE [17, 18], although plasma BChE is more
sensitive to some OPs than RBC AChE. Furthermore, both cholinesterases are found in
blood, an ideal matrix for bio-marker analysis.
In 1961, Ellman et al. reported a colorimetric enzymatic assay that is currently the standard
method for determining occupational or accidental OP exposures [19]. The Ellman assay
uses acetylthiocholine or butyrylthiocholine for determining AChE or BChE activity,
respectively. Other methods for monitoring cholinesterases have been reported [20], but the
Ellman assay has remained the method of choice due to its advantages, being an
inexpensive, simple and rapid assay. Despite the advantages, the Ellman assay has also some
important drawbacks. It is not an accurate assay at low levels of inhibition (20% or less) [17,
21–23]. OPs causing delayed or chronic toxicity without significant inhibition of
cholinesterases cannot be monitored by this method [7, 24]. In addition, it requires a pre-
exposure determination of baseline activity level in order to overcome intra- and inter-
individual activity variability, and for more accurate assessment of low level inhibition [25,
26]. The pH of the buffers used in the assay and the concentration of substrate can also be
critical in obtaining consistent results [20]. Furthermore, the temperature of sample storage
is also an important issue. Spontaneous reactivation of the inhibitor-enzyme complex is
observed at ambient temperature with some OP inhibitors [20]. OP inhibitions are not
irreversible until a structural reorganization, ‘aging’, of the inhibitor-enzyme complex
happens (see Section 4). Another limitation is the impossibility of identifying the OP
compound responsible for the observed inhibition. Moreover, because the replacement of
inactive enzyme by de novo synthesized protein can occur rapidly, this method is less
amenable for retrospective analyses [22, 23]. When comparing plasma BChE vs. RBC
AChE, AChE determination can present further disadvantages, resulting from difficulties in
reproducible pipetting and washing of the RBCs, or from a potential interference by
hemoglobin [20, 27]. In terms of enzyme availability, humans have ten times more BChE
than AChE [28], plasma is an easier matrix to handle than RBCs and, as noted above, BChE
may be more sensitive to inhibition by some OPs than AChE. Despite these disadvantages,
RBC AChE has a longer half-life than plasma BChE (33 vs. 11 days, respectively) [29],
enabling evaluation of exposures after longer periods of time.
4. OP binding to the active-site serine and proteomics
Inhibition of serine hydrolases by OPs is mainly due to the formation of a covalent bond
between the phosphor-alkoxy moiety of the OP compound and the hydroxyl residue of the
catalytic serine of the active site of these enzymes, with the resulting release of the OP
‘leaving group’. The OP adduct can suffer further dealkylation through a process called
‘aging’, probably assisted by residues near the active site of the enzyme. Although the initial
covalent bond is usually reversible, the aging (loss of one alkoxy group) enhances the
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stability of the OP adduct bound to the enzyme, preventing the dissociation of the enzyme-
inhibitor complex [12]. The OP-adducted protein will remain in circulation for a length of
time dependent on the half-life of the enzyme, generally much longer than the resident time
of the OP or its metabolites.
The fact that serine hydrolases are modified by OPs provides another means for identifying
the specific OP exposures with the use of liquid chromatography and tandem mass
spectrometry (LC–MS/MS) to detect and quantify modified (OP-adducted) proteins. LC–
MS/MS is ideal for the identification of a wide variety of protein modifications. It is a highly
sensitive and precise technique that can perform accurate mass readings, allowing effective
identification of different adducts with similar or identical masses. LC–MS/MS can quantify
adducted and non-adducted enzymes, making it suitable for quantitative retrospective
analysis. It does not require a baseline activity measurement for the individual, eliminating
the need of pre-exposure bleeds. Part of the original OP structure is released during the
reaction of the OP with the active-site serine and another part during the aging process;
therefore MS may provide ambiguous or limited identification of the specific OP of
exposure. LC–MS/MS also has some limitations or disadvantages, such as being time
consuming, costly, limited by reactivation, and requiring well-trained personnel [16, 23].
Application of MS to the study of OP exposures was first reported in 2001, using in vitro
inhibited equine serum BChE [30]. The first ‘in vivo’ application came just one year later
[31], and since has become a field of intense research [32]. MS has also proven to be useful
for the identification of new biomarkers of OP exposure [33]. Both LC and MALDI-TOF
MS have been reported to be useful in the identification of OP exposures from either
insecticides or nerve agents [21, 33–39]. Most of these studies have focused on BChE, since
it is an abundant plasma protein that is easy to obtain and has been extensively studied as a
biomarker of OP exposure. The methods described in these studies involve either pure
BChE or partial purification of OP-adducted BChE, followed by proteolytic digestion (e.g.,
pepsin, trypsin or chymotrypsin) and LC–MS/MS or MALDI-TOF analysis. Even though
MS provides high sensitivity analyses, plasma is still a very complex matrix and purification
of the biomarker protein (or modified peptide) facilitates analysis. One reported partial
purification of BChE was achieved by affinity chromatography, which is time consuming,
requires specific resins and a large volume of sample, and thus limits the standardization of
the assay for high-throughput. Other studies, including those from our laboratory, that also
monitor OP exposures by LC–MS/MS, have described the use of immunomagnetic beads
coupled to a specific anti-BChE antibody (Fig. 1), a procedure that should overcome the
limitations of affinity chromatography for biomarker purification [15, 40–42].
Immunomagnetic separation (IMS) protocols are faster, require smaller quantities of starting
material and can be easily adapted for automated high-throughput analysis. The affinity
column approach, however, is useful when large quantities of analyte are required to detect a
low level of OP adduction.
5. Verification of OP exposures using IMS coupled to LC–MS/MS
In developing analyses for OP-adducted biomarker proteins, our goal was to develop a
protocol that (1) used low volumes of plasma, (2) is rapid and easy to perform, (3) is more
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sensitive than the Ellman assay, (4) does not require a separate blood draw for determination
of baseline activity level, and (5) is easily automated for high-throughput. The main
rationale for these goals was the achievement of a rapid procedure that could be used for any
event of human exposure resulting in cholinesterase inhibition. Two types of exposure are
described below as examples of IMS coupled to LC–MS/MS analyses.
5.1. Aerotoxic syndrome
Tricresyl phosphate (TCP) is an OP compound used as an anti-wear additive in jet engine
lubricants and hydraulic fluids [43, 44]. During Prohibition, the ortho isomer of TCP was
used to adulterate alcoholic ginger extracts, causing thousands of cases of paralysis in the
United States [45]. The air supply for the aircraft cabin is directed unfiltered to the aircraft
cabin and flight deck from the aircraft engine along the combustion pathway of the engine
(referred to as bleed air) [46]. When engine seals wear or fail, significant levels of engine oil
fumes can enter the aircraft cabin (fume event). Even under normal operation conditions,
some TCP may enter the cabin. For instance, TCP was detected on 23% of the 100 flights
monitored in a recent Cranfield University study [47]. It has been estimated (from a survey
over an 18-month period) that an average of 0.86 fume events occur per day, although this is
suspected to be an underestimation due to underreports of the total number of fume events
[46]. During the past 25 years, there have been an increasing number of reports of mainly
pilots and flight attendants, experiencing a series of symptoms following fume events,
including tremors, dizziness, nausea, disorientation; or long-term numbness, memory loss
and fatigue [38, 39, 41]. These symptoms have been referred to as aerotoxic syndrome [48].
Once the TCP enters the human body, it is bioactivated by the liver cytochromes P450 to the
toxic molecule, 2-(ortho-cresyl)-4H-1, 3, 2-benzodioxaphosphoran-2-one, also known as
cyclic saligenin cresyl phosphate (CBDP) (Fig. 2) [49]. Although it is unlikely that the
symptoms reported above are caused by inactivation of BChE by CBDP, BChE can
nonetheless serve as a biomarker of TCP exposure.
Using immunomagnetic beads conjugated with a monoclonal BChE antibody (Fig. 1), we
have been able to purify plasma BChE to a high degree of purity starting with 200 μl of
plasma or less in only one step [41]. Initially the bound BChE was eluted with acetic acid,
digested with chymotrypsin and analyzed by LC–MS/MS. The current protocol avoids the
elution step and performs the chymotrypsin digestion on beads, releasing the digested
peptides prior to loading the sample to the LC–MS/MS, as depicted in Fig. 1. The rationale
for this was to obtain a protocol amenable to automation. The active-site peptide sequence
monitored was GESAGAASVSLH (the active-site serine is underlined) [41]. We detected
BChE adducted with both cresyl phosphate (+170 Da) and phosphate (+80 Da) adducts on
the serine 198 of the active site of in vitro exposed samples to CBDP (Fig. 2) [41]. The
identification of phosphorylated active-site serine of BChE from passengers on a
commercial flight has been reported. However, the amount of modified BChE was low
(ranging from 0.05 to 3%) [39]. The limit of detection of the IMS-LC–MS/MS protocol for
TCP exposures is about 5%, more sensitive than the Ellman assay, but not yet sensitive
enough to detect very low levels of exposures. We are currently focusing on identifying
more sensitive biomarkers for monitoring TCP exposures.
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OP insecticides are widely used in agriculture. Despite the drawbacks described above, the
Ellman assay is currently the standard method used for monitoring OP insecticide exposures.
In the United States, the states of California and Washington have ongoing monitoring
programs where agricultural workers at high risk of OP insecticide exposure are tested for
both AChE and BChE inhibition prior to and during the work/spray season. The use of the
Ellman assay for monitoring their cholinesterases requires obtaining a pre-season bleed so
they can compare their cholinesterase basal levels with their levels during the work season
[50, 51]. If their cholinesterase levels decrease 40% or more from the basal activity levels,
workers are removed from the exposure environment, without loss of wages, until their
cholinesterase levels return to 80% of their basal level. The goal of these mandatory
monitoring programs is to protect the health and safety of the agricultural workers.
The use of MS for monitoring these agricultural workers should overcome many of the
limitations of the Ellman assay. We have used the following improved version of the IMS
coupled with the LC–MS/MS protocol detailed above where 100 μl of plasma is incubated
with immunomagnetic beads conjugated with a monoclonal BChE antibody. Following
washing of the BChE/bead complex, an on-bead digestion of the bound BChE with
chymotrypsin is carried out followed by LC–MS/MS analysis of the peptide containing the
active-site serine 198. Our goal was to monitor a cohort of Washington State agricultural
workers and compare the results with the Ellman assay inhibition measurements of the same
workers.
The preliminary in vitro experiments focused on characterizing BChE active-site serine
adducts resulting from chlorpyrifos oxon (CPO) and azinphos methyl oxon (AZO)
inhibition; the toxic oxon metabolites of two commonly used OP insecticides. The same
active-site dodecapeptide described above was obtained from the chymotrypsin digestion of
BChE. We were able to identify the diethyl phosphoserine and mono-ethyl phosphoserine
adducts following exposure to CPO, which revealed a gain of 154 or 126 Da compared to
the unmodified BChE active-site peptide, respectively (Fig. 3A). Following incubation with
AZO, the analyzed BChE active-site peptides revealed di-methyl phosphoserine (gain of 126
Da) and mono-methyl phosphoserine (gain of 112 Da) adducts on serine 198 (Fig. 3B). The
limit of detection of this method is about 1–2%.
We are currently carrying out LC–MS/MS analysis of plasma samples from 128 agricultural
workers, whose BChE activity inhibition levels are known. The preliminary data indicate
exposure of some agricultural workers to CPO (vs. AZO) (Fig. 4). No AZO exposure was
identified during our preliminary analyses. The IMS purification coupled with LC–MS/MS
analysis of adducted BChE peptides correlated well with the Ellman activity inhibition
assay; however more analyses need to be carried out to corroborate these findings. With
some of the analyzed samples, the Ellman assay reported a gain of activity compared with
the basal measurement of BChE activity, while the LC–MS/MS identified either no adducts
or adducts indicating low levels of CPO exposure (data not shown).
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6. Conclusions and future perspectives
Early detection of OP exposures can allow for clinical interventions before severe symptoms
occur and an improved follow up of the recovery of the subject. A 50% inhibition of neural
AChE or greater is necessary for developing anti-cholinergic symptoms [52]. The LC–
MS/MS analysis of OP modified BChE has several advantages over the currently used
colorimetric enzyme activity assays. The analysis does not require a separate blood draw for
the determination of baseline activity levels, it provides a more accurate measurement of the
percentage modification of the active-site serine, and it also provides some information
about the OP that adducted the active-site serine (e.g., a methyl- or ethyl-based insecticide).
The focus on the use of MS analysis for biomonitoring exposures to OP compounds
represents a significant advantage for the identification and characterization of biomarkers
of exposure. In recent years, there have been important improvements in MS technology,
paving the way for the use of these analyses in standard clinical laboratories. Some of the
current limitations of MS, including costs of analyses, time required for analyses, and the
requirement for highly trained workers may be overcome in the near future.
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Immunomagnetic bead separation of BChE coupled to LC–MS/MS analysis. This protocol
efficiently purifies human BChE from 100 μl of plasma or less in one single step, and is
readily adaptable for high-throughput analytical protocols. Samples are digested on-beads
with chymotrypsin (CHY) and analyzed by LC–MS/MS.
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Bioactivation of tricresyl phosphate (TCP) to the highly toxic metabolite cyclic saligenin
cresyl phosphate (CBDP) by the liver cytochromes P450. CBDP affects both the central
(CNS) and peripheral nervous system (PNS). CBDP inhibits BChE yielding a cresyl
phosphate on the serine 198 of the active site that ages to phosphoserine.
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OP insecticides and MS analysis using in vitro inhibited BChE. (A) Metabolism, BChE
adduction and aging of chlorpyrifos. The MS analysis of the BChE active-site peptide
detected both adducts, the di-ethyl phosphoserine and the aged mono-ethyl phosphoserine.
(B) Metabolism, BChE adduction and aging of azinphos methyl. The MS analysis of the
BChE active-site peptide detected both adducts, the di-methyl phosphoserine and the aged
mono-methyl phosphoserine.
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Identification of chlorpyrifos exposure in plasma of an agricultural worker. The adduct on
the active-site serine corresponds to the aged mono-ethyl phosphate.
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